ATE253061T1 - Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide - Google Patents

Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide

Info

Publication number
ATE253061T1
ATE253061T1 AT99926680T AT99926680T ATE253061T1 AT E253061 T1 ATE253061 T1 AT E253061T1 AT 99926680 T AT99926680 T AT 99926680T AT 99926680 T AT99926680 T AT 99926680T AT E253061 T1 ATE253061 T1 AT E253061T1
Authority
AT
Austria
Prior art keywords
cancer
dicarboxamide
furan
thiophene
useful
Prior art date
Application number
AT99926680T
Other languages
English (en)
Inventor
Denis Labrecque
Serge Lamothe
Marc Courchesne
Laval Chan
Giorgio Attardo
Karen Meerovitch
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Application granted granted Critical
Publication of ATE253061T1 publication Critical patent/ATE253061T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
AT99926680T 1998-06-29 1999-06-29 Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide ATE253061T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9106398P 1998-06-29 1998-06-29
PCT/IB1999/001221 WO2000000486A1 (en) 1998-06-29 1999-06-29 Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE253061T1 true ATE253061T1 (de) 2003-11-15

Family

ID=22225790

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99926680T ATE253061T1 (de) 1998-06-29 1999-06-29 Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide

Country Status (6)

Country Link
US (1) US6960594B2 (de)
EP (1) EP1091952B1 (de)
AT (1) ATE253061T1 (de)
AU (1) AU4385399A (de)
DE (1) DE69912432D1 (de)
WO (1) WO2000000486A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6274620B1 (en) 1999-06-07 2001-08-14 Biochem Pharma Inc. Thiophene integrin inhibitors
DE60130910T2 (de) 2000-04-17 2008-07-10 Ucb Pharma, S.A. Enamin-derivate als zell-adhäsionsmoleküle
FR2808798A1 (fr) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
CN101624391A (zh) * 2001-06-11 2010-01-13 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
CN100413861C (zh) 2002-12-10 2008-08-27 维勒凯姆制药股份有限公司 用于治疗或预防黄病毒感染的化合物
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US7569600B2 (en) * 2005-05-13 2009-08-04 Virochem Pharma Inc. Compounds and methods for the treatment of prevention of Flavivirus infections
CN102675279A (zh) 2006-11-15 2012-09-19 Viro化学制药公司 用于治疗或预防黄病毒属感染的噻吩类似物
WO2011025706A2 (en) * 2009-08-26 2011-03-03 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
US8337334B2 (en) * 2009-09-14 2012-12-25 Nike, Inc. Golf balls with clusters of dimples having non-uniform dimple profiles
AU2014240950B2 (en) 2013-03-29 2018-11-01 Avoscience, Llc Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2017189865A1 (en) 2016-04-27 2017-11-02 Avoscience, Llc Lipidic furan, pyrrole, and thiophene compounds for use in the treatment of atrophic vaginitis
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3322878B2 (ja) * 1992-10-14 2002-09-09 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプターアンタゴニスト
WO1997037655A1 (en) * 1996-04-10 1997-10-16 Merck & Co., Inc. αvβ3 ANTAGONISTS

Also Published As

Publication number Publication date
EP1091952A1 (de) 2001-04-18
AU4385399A (en) 2000-01-17
US20020137947A1 (en) 2002-09-26
US6960594B2 (en) 2005-11-01
EP1091952B1 (de) 2003-10-29
DE69912432D1 (de) 2003-12-04
WO2000000486A1 (en) 2000-01-06

Similar Documents

Publication Publication Date Title
ATE253061T1 (de) Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
WO2002002518A3 (en) Compounds to treat alzheimer's disease
WO2002002520A8 (en) Compounds to treat alzheimer's disease
JP2003524577A5 (de)
ATE348808T1 (de) Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
DE69805202D1 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
ATE299890T1 (de) Inhibitoren von gamma-secretase
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
SE0104248D0 (sv) Method of treatment
ATE315390T1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
DE69914084D1 (de) Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen
NO994330D0 (no) Metode for behandling av en tumor
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE402257T1 (de) Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit
DE69800859D1 (de) Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
ATE211921T1 (de) Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata
DE60026883D1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
BR0312470A (pt) Composto, uso do mesmo, composição farmacêutica, método de tratar e/ou prevenir câncer, e, processo para preparar o composto
DE60015791D1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE212845T1 (de) Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
DE69822626D1 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
ATE293972T1 (de) Behandlung von chronischen schmerzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties